Business
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo
About this update from Silo Pharma, Inc.
[{"type":"text","content":"Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System\nEnglewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore relating to a study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. According to the National Multiple Sclerosis Society, an estimated 1 million people live with MS in the United States. Silo Pharma is seeking to develop treatments, including the use of targeted drug delivery to the Central Nervous System (CNS) as a means of overcoming many of the limitations of current therapies. The study will seek to identify the various cell types that are responsive to a series of peptides to understand how drug-carrying liposomes ultimately interact with the CNS tissue cells. “We are to be collaborating with researches at the University to begin a study of this novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. This study is an important step in gathering research and data to treat rare neurologic diseases with the CNS peptide,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “We believe that, when combined with the findings of our previously announced investigator-sponsored study, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson's disease and to understand its mechanism of action, we will gain valuable data needed to analyze the potential of these peptides to be used in combination with psilocybin, LSD, or traditional drugs, as potential therapeutic agents.” About Silo Pharma Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and th...